Drug Trial Radar · NCT06084884
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
94
Planned (sponsor's estimate)
Start
Dec 14, 2023
Primary completion
Dec 13, 2027
Study completion Dec 13, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 16, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase I/II study to evaluate AZD5851 in patients with GPC3+ advanced/recurrent hepatocellular carcinoma.
Conditions
- Hepatocellular Carcinoma
Interventions
AZD5851Biological
Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce AZD5851. During AZD5851 production, subjects may receive bridging therapy for disease control. Upon successful generation of AZD5851 product, subjects will receive treatment with AZD5851 therapy. Study treatment will include lymphodepleting chemotherapy followed by one dose of AZD5851 administered by intravenous (IV) infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 1. Incidence of participants with dose-limiting toxicities (DLTs), adverse events (AEs), including adverse events of special interest (AESI) and serious adverse events (SAEs). Determination of the recommended dose of AZD5851 for expansion phaseTime frame: Through study completion, an average of 2 years
Locations
19 sites in 3 countries. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona
Research Site
Duarte, California
Research Site
Los Angeles, California
Research Site
Orange, California
Research Site
San Francisco, California
Research Site
Washington D.C., District of Columbia
Research Site
Jacksonville, Florida
Research Site
Atlanta, Georgia
Research Site
Westwood, Kansas
Research Site
Rochester, Minnesota
Research Site
Hackensack, New Jersey
Research Site
New York, New York
Research Site
Columbus, Ohio
Research Site
Portland, Oregon
Research Site
Philadelphia, Pennsylvania
Research Site
Pittsburgh, Pennsylvania
Research Site
Kashiwa, Japan
Research Site
Osakasayama-shi, Japan
Research Site
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.